Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept in early diffuse cutaneous systemic sclerosis
NCT06375005Phase 2Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jan 2025
- Primary completion
- Jan 2027
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of telitacicept in diffuse cutaneous systemic sclerosis (dcSSc), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Started Jan 2025; status: recruiting.
02
Drugs
telitacicept
03
Conditions
diffuse cutaneous systemic sclerosis (dcSSc)
Beyond the preview
Go deeper on NCT06375005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06375005.